Value of Nonpharmacological Interventions for People With an Acquired Brain Injury : A Systematic Review of Economic Evaluations
Copyright © 2022. Published by Elsevier Inc..
OBJECTIVES: Acquired brain injury (ABI) has long-lasting effects, and patients and their families require continued care and support, often for the rest of their lives. For many individuals living with an ABI disorder, nonpharmacological rehabilitation treatment care has become increasingly important care component and relevant for informed healthcare decision making. Our study aimed to appraise economic evidence on the cost-effectiveness of nonpharmacological interventions for individuals living with an ABI.
METHODS: This systematic review was registered in PROSPERO (CRD42020187469), and a protocol article was subject to peer review. Searches were conducted across several databases for articles published from inception to 2021. Study quality was assessed according the Consolidated Health Economic Evaluation Reporting Standards checklist and Population, Intervention, Control, and Outcomes criteria.
RESULTS: Of the 3772 articles reviewed 41 publications met the inclusion criteria. There was a considerable heterogeneity in methodological approaches, target populations, study time frames, and perspectives and comparators used. Keeping these issues in mind, we find that 4 multidisciplinary interventions studies concluded that fast-track specialized services were cheaper and more cost-effective than usual care, with cost savings ranging from £253 to £6063. In 3 neuropsychological studies, findings suggested that meditated therapy was more effective and saved money than usual care. In 4 early supported discharge studies, interventions were dominant over usual care, with cost savings ranging from £142 to £1760.
CONCLUSIONS: The cost-effectiveness evidence of different nonpharmacological rehabilitation treatments is scant. More robust evidence is needed to determine the value of these and other interventions across the ABI care pathway.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research - 25(2022), 10 vom: 30. Okt., Seite 1778-1790 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mitchell, Eileen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acquired brain injury |
|---|
| Anmerkungen: |
Date Completed 18.10.2022 Date Revised 16.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jval.2022.03.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340543140 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340543140 | ||
| 003 | DE-627 | ||
| 005 | 20231226005543.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jval.2022.03.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1135.xml |
| 035 | |a (DE-627)NLM340543140 | ||
| 035 | |a (NLM)35525832 | ||
| 035 | |a (PII)S1098-3015(22)00156-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mitchell, Eileen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Value of Nonpharmacological Interventions for People With an Acquired Brain Injury |b A Systematic Review of Economic Evaluations |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.10.2022 | ||
| 500 | |a Date Revised 16.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022. Published by Elsevier Inc. | ||
| 520 | |a OBJECTIVES: Acquired brain injury (ABI) has long-lasting effects, and patients and their families require continued care and support, often for the rest of their lives. For many individuals living with an ABI disorder, nonpharmacological rehabilitation treatment care has become increasingly important care component and relevant for informed healthcare decision making. Our study aimed to appraise economic evidence on the cost-effectiveness of nonpharmacological interventions for individuals living with an ABI | ||
| 520 | |a METHODS: This systematic review was registered in PROSPERO (CRD42020187469), and a protocol article was subject to peer review. Searches were conducted across several databases for articles published from inception to 2021. Study quality was assessed according the Consolidated Health Economic Evaluation Reporting Standards checklist and Population, Intervention, Control, and Outcomes criteria | ||
| 520 | |a RESULTS: Of the 3772 articles reviewed 41 publications met the inclusion criteria. There was a considerable heterogeneity in methodological approaches, target populations, study time frames, and perspectives and comparators used. Keeping these issues in mind, we find that 4 multidisciplinary interventions studies concluded that fast-track specialized services were cheaper and more cost-effective than usual care, with cost savings ranging from £253 to £6063. In 3 neuropsychological studies, findings suggested that meditated therapy was more effective and saved money than usual care. In 4 early supported discharge studies, interventions were dominant over usual care, with cost savings ranging from £142 to £1760 | ||
| 520 | |a CONCLUSIONS: The cost-effectiveness evidence of different nonpharmacological rehabilitation treatments is scant. More robust evidence is needed to determine the value of these and other interventions across the ABI care pathway | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a acquired brain injury | |
| 650 | 4 | |a economic evaluation | |
| 650 | 4 | |a nonpharmacological interventions | |
| 650 | 4 | |a stroke | |
| 650 | 4 | |a systematic review | |
| 700 | 1 | |a Ahern, Elayne |e verfasserin |4 aut | |
| 700 | 1 | |a Saha, Sanjib |e verfasserin |4 aut | |
| 700 | 1 | |a McGettrick, Grainne |e verfasserin |4 aut | |
| 700 | 1 | |a Trépel, Dominic |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research |d 1998 |g 25(2022), 10 vom: 30. Okt., Seite 1778-1790 |w (DE-627)NLM115934545 |x 1524-4733 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2022 |g number:10 |g day:30 |g month:10 |g pages:1778-1790 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jval.2022.03.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2022 |e 10 |b 30 |c 10 |h 1778-1790 | ||